Barclays Maintains Overweight on AbbVie, Raises Price Target to $185
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on AbbVie (NYSE:ABBV) and raises the price target from $175 to $185, indicating a positive outlook on the stock.
February 05, 2024 | 11:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Carter Gould maintains an Overweight rating on AbbVie and raises the price target from $175 to $185.
The increase in price target by a reputable analyst like Carter Gould from Barclays signals a strong confidence in AbbVie's future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100